Vinn,
Excellent post and what a progressive coy to be partnership with.
TEVA's no 1 selling drug is its $3 billion multiple sclerosis(MS) drug Copaxone which currently makes up 21% of sales(coming off patent in 2013). So TEVAs acquisition of CEPH now has the merged entity @ $20bn - talk about forward planning by this super Global Pharma.
And if the Cardio Franshise wanst enough, just to make sure that MSB retains its NO 1 'sweetheart' title within the TEVA family, the Blaster is looking at developing an MS application as part of its Intravenous Program /Francshise ( page 5 annual report).
Great 2012 coming on !
Cheers to all holders.
this company is now a substantial holder ...., page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |